Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
15.90
+0.38 (2.45%)
At close: Sep 8, 2026, 4:00 PM EDT
15.56
+0.04 (0.26%)
Pre-market: Sep 9, 2026, 7:16 AM EDT
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $913.24 million as of September 8, 2026. Its market cap has increased by 463.88% in one year.
Market Cap
913.24M
Enterprise Value
675.33M
1-Year Change
463.88%
Ranking
Category
Stock Price
$15.90
ChartMarket Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $913.24M, an increase of 126.50%. That is a compound annual growth rate of 17.45%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 8, 2026 | 913.24M | 378.19% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Olema Pharmaceuticals | 947.60M |
| Wave Life Sciences | 946.82M |
| Design Therapeutics | 945.61M |
| SpyGlass Pharma | 941.39M |
| Ardelyx | 928.22M |
| Annexon | 896.71M |
| Cybin | 894.99M |
| Crescent Biopharma | 894.54M |